Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 8:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Obesity
Interventions
exenatide, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Peoria, Arizona • Tucson, Arizona • Santa Ana, California + 11 more
Conditions
Diabetes Mellitus, Type 2
Interventions
exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
60
States / cities
Birmingham, Alabama • Anaheim, California • Bellflower, California + 57 more
Conditions
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Exenatide
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Impaired Glucose Tolerance
Interventions
Exenatide, Metformin
Drug
Lead sponsor
St. Paul Heart Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Saint Louis Park, Minnesota • Saint Paul, Minnesota
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

NCT00456885
Conditions
Obesity, Impaired Glucose Tolerance
Interventions
exenatide, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
25 Years to 60 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

NCT01381926
Conditions
Type 2 Diabetes Mellitus, Bone Remodeling
Interventions
exenatide, Saline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
45 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Type 2 Diabetes
Interventions
Exenatide, Glargine, Rapid-acting insulin analogs
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Type 2 Diabetes
Interventions
placebo, exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
40
States / cities
Peoria, Arizona • Phoenix, Arizona • Buena Park, California + 37 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide, Albiglutide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky • Dallas, Texas
Completed Phase 2Phase 3 Interventional Results available

Role of Exenatide in NASH-a Pilot Study

NCT00650546
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Exenatide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Indianapolis, Indiana • Kansas City, Missouri • San Antonio, Texas
Completed Phase 3 Interventional Results available

A Study in Participants With Type 2 Diabetes Mellitus

NCT01064687
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Exenatide, Placebo, Metformin, Pioglitazone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
78
States / cities
Goodyear, Arizona • Phoenix, Arizona • Cathedral City, California + 75 more
Completed Phase 1Phase 2 Interventional Results available

Effects of Exenatide on Hypothalamic Obesity

NCT01061775
Conditions
Hypothalamic Obesity
Interventions
Exenatide
Drug
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
10 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Orange, California • Saint Paul, Minnesota
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Exenatide, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, sitagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
19
States / cities
Los Angeles, California • Spring Valley, California • Miami, Florida + 15 more
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Exendin-4 SC, Placebo SC
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Diabetes Mellitus Type 2
Interventions
exenatide, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
87
States / cities
Haleyville, Alabama • Mobile, Alabama • Montgomery, Alabama + 78 more
Conditions
Type 2 Diabetes
Interventions
Insulin Glargine, Metformin, Prandial insulin, Exenatide
Drug
Lead sponsor
University of Washington
Other
Eligibility
40 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 9 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide (AC2993), Insulin glargine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
21
States / cities
San Diego, California • San Mateo, California • Fort Myers, Florida + 18 more
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Placebo 0.01 mL, Placebo 0.02 mL, Placebo 0.03 mL, Placebo 0.04 mL, AC2993 2.5 mcg, AC2993 5.0 mcg, AC2993 7.5 mcg, AC2993 10.0 mcg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
33
States / cities
Birmingham, Alabama • Anaheim, California • Bellflower, California + 28 more
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Idaho Falls, Idaho • Indianapolis, Indiana
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide, Glipizide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Washington D.C., District of Columbia • San Antonio, Texas
Conditions
Diabetes Mellitus
Interventions
placebo, exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Temple, Arizona • Colorado Springs, Colorado • Honolulu, Hawaii + 2 more
Conditions
Type 2 Diabetes
Interventions
exenatide, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Rochester, Minnesota • Portland, Oregon